<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-KEN25380-2PX-16-9V2">
    <metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 S2336 IS: Halting the Epidemic of Addiction and Loss Act of 2025</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2025-07-17</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
        <distribution-code>II</distribution-code>
        <congress>119th CONGRESS</congress>
        <session>1st Session</session>
        <legis-num>S. 2336</legis-num>
        <current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
        <action>
            <action-date date="20250717">July 17, 2025</action-date>
            <action-desc><sponsor name-id="S287">Mr. Cornyn</sponsor> (for himself and <cosponsor name-id="S388">Ms. Hassan</cosponsor>) introduced the following bill; which was
                read twice and referred to the <committee-name committee-id="SSHR00">Committee on
                    Health, Education, Labor, and Pensions</committee-name></action-desc>
        </action>
        <legis-type>A BILL</legis-type>
        <official-title>To ensure references to opioid overdose reversal agents in certain grant
            programs of the Department of Health and Human Services are not limited to
            naloxone.</official-title>
    </form>
    <legis-body style="OLC">
        <section id="idcae4002bbccb485599c9fce5ff8f29c0" section-type="section-one">
            <enum>1.</enum>
            <header>Short title</header>
 <text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Halting the Epidemic of Addiction and Loss Act of 2025</short-title></quote>.</text>
        </section>
        <section id="H54428B560EC543649A578F96F20F4A7E">
            <enum>2.</enum>
            <header>References to opioid overdose reversal agents in HHS grant programs</header>
            <subsection id="H0788A0B6EA504892A931927E0B19B570">
                <enum>(a)</enum>
                <header>In general</header>
 <text>The Secretary of Health and Human Services shall ensure that, as appropriate, whenever the Department of Health and Human Services issues a regulation or guidance for any grant program addressing opioid misuse and use disorders, any reference to an opioid overdose reversal drug (such as a reference to naloxone) is inclusive of any opioid overdose reversal drug that has been approved under section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) for emergency treatment of a known or suspected opioid overdose.</text>
            </subsection>
            <subsection id="HD1F8B5C00B0745B38B965A093C4585C6">
                <enum>(b)</enum>
                <header>Existing references</header>
                <paragraph id="H877C250BEA284FE993E3123D76837147">
                    <enum>(1)</enum>
                    <header>Update</header>
 <text>Not later than one year after the date of enactment of this Act, the Secretary of Health and Human Services shall update all references described in paragraph (2) to be inclusive of any opioid overdose reversal drug that has been approved or otherwise authorized for use by the Food and Drug Administration.</text>
                </paragraph>
                <paragraph id="H286C22EE03B74FDABC194E06B8AE1094">
                    <enum>(2)</enum>
                    <header>References</header>
 <text>A reference described in this paragraph is any reference to an opioid overdose reversal drug (such as naloxone) in any regulation or guidance of the Department of Health and Human Services that—</text>
                    <subparagraph id="H744EB41BE7E041E89CD47BEBED355DB4">
                        <enum>(A)</enum>
 <text>was issued before the date of enactment of this Act; and</text> </subparagraph> <subparagraph id="H2BABE64D7A84459482368067F087A584"> <enum>(B)</enum> <text>is included in—</text>
                        <clause id="H0FEC90507D2849A6950110B16BB4AE58">
                            <enum>(i)</enum>
 <text>the grant program for State and Tribal response to opioid use disorders under section 1003 of the 21st Century Cures Act (<external-xref legal-doc="usc" parsable-cite="usc/42/290ee-3a">42 U.S.C. 290ee–3a</external-xref>) (commonly referred to as <quote>State Opioid Response Grants</quote> and <quote>Tribal Opioid Response Grants</quote>); or</text>
                        </clause>
                        <clause id="H063567BC626F48F38E969006A6CC07CA">
                            <enum>(ii)</enum>
 <text>the grant program for priority substance use disorder prevention needs of regional and national significance under section 516 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/290bb-22">42 U.S.C. 290bb–22</external-xref>).</text>
                        </clause>
                    </subparagraph>
                </paragraph>
            </subsection>
        </section>
    </legis-body>
</bill>

